The US Food and Drug Administration confirmed in guidance published on 19 August that it will generally issue complete response letters to drug application sponsors when it has concerning information about their manufacturing facilities but cannot conduct a timely pre-approval inspection, or PAI, due to the novel coronavirus pandemic.
Alternatively, the agency said if it lacks adequate information to decide whether a facility is acceptable, it may defer action on an application for a